The TAK-003 dengue vaccine was licensed in Europe in December 2022, and the official recommendations from most EU countries are still under formulation. To support policymakers, we performed a meta-analysis to quantify TAK-003's immunogenicity, efficacy and safety among seronegative and seropositive populations after the administration of one or two vaccine doses. We included trials retrieved from MEDLINE, Scopus and ClinicalTrials.gov. The outcomes were the rates of seroconversion, virologically confirmed dengue fever and serious adverse events after each vaccine dose. Data were combined using random-effect proportion or head-to-head meta-analyses. We retrieved a total of 19 datasets, including >20,000 participants. TAK-003 showed an excellent safety profile, and the immunogenicity after two doses against the four DENV serotypes was >= 90% among both adults and children/adolescents who were either seronegative or seropositive at baseline. A single dose was able to elicit a high immunogenic response among adults (>= 70%) and children/adolescents (>= 90%). The primary two-dose immunization course halved the risk of all types of virologically confirmed dengue fever among seropositive children/adolescents, but seronegative minors were only protected against the diseases caused by DENV-1 and DENV-2. Overall, the results support the use of TAK-003 for the prevention of dengue fever in the pediatric population of endemic countries. Uncertainties remain on the use of a single vaccine dose in non-endemic countries.

Flacco, M.E., Bianconi, A., Cioni, G., Fiore, M., Calò, G.L., Imperiali, G., et al. (2024). Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis. VACCINES, 12(7), 1-13 [10.3390/vaccines12070770].

Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis

Bianconi, Alessandro
Co-primo
Conceptualization
;
Fiore, Matteo
Methodology
;
Manzoli, Lamberto
Ultimo
Writing – Original Draft Preparation
2024

Abstract

The TAK-003 dengue vaccine was licensed in Europe in December 2022, and the official recommendations from most EU countries are still under formulation. To support policymakers, we performed a meta-analysis to quantify TAK-003's immunogenicity, efficacy and safety among seronegative and seropositive populations after the administration of one or two vaccine doses. We included trials retrieved from MEDLINE, Scopus and ClinicalTrials.gov. The outcomes were the rates of seroconversion, virologically confirmed dengue fever and serious adverse events after each vaccine dose. Data were combined using random-effect proportion or head-to-head meta-analyses. We retrieved a total of 19 datasets, including >20,000 participants. TAK-003 showed an excellent safety profile, and the immunogenicity after two doses against the four DENV serotypes was >= 90% among both adults and children/adolescents who were either seronegative or seropositive at baseline. A single dose was able to elicit a high immunogenic response among adults (>= 70%) and children/adolescents (>= 90%). The primary two-dose immunization course halved the risk of all types of virologically confirmed dengue fever among seropositive children/adolescents, but seronegative minors were only protected against the diseases caused by DENV-1 and DENV-2. Overall, the results support the use of TAK-003 for the prevention of dengue fever in the pediatric population of endemic countries. Uncertainties remain on the use of a single vaccine dose in non-endemic countries.
2024
Flacco, M.E., Bianconi, A., Cioni, G., Fiore, M., Calò, G.L., Imperiali, G., et al. (2024). Immunogenicity, Safety and Efficacy of the Dengue Vaccine TAK-003: A Meta-Analysis. VACCINES, 12(7), 1-13 [10.3390/vaccines12070770].
Flacco, Maria Elena; Bianconi, Alessandro; Cioni, Giovanni; Fiore, Matteo; Calò, Giovanna Letizia; Imperiali, Gianmarco; Orazi, Vittorio; Tiseo, Marco...espandi
File in questo prodotto:
File Dimensione Formato  
Manzoli L Vaccines (Dengue) 2024.pdf

accesso aperto

Descrizione: Article
Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 759.17 kB
Formato Adobe PDF
759.17 kB Adobe PDF Visualizza/Apri
vaccines-12-00770-s001.zip

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 999.45 kB
Formato Zip File
999.45 kB Zip File Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/979801
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact